← Eichor
Condition: Advanced Gastroesophageal Junction Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Gastroesophageal Junction Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients Wi
Phase 2/Phase 3 · 10 location(s) · Beijing Biostar Pharmaceuticals Co., Ltd. · NCT06841679Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/Phase 2 · 18 location(s) · AstraZeneca · NCT06921928Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-posit
Phase N/A · 36 location(s) · Daiichi Sankyo · NCT06846996Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05170503A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT04982276A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemothera
Phase 2 · 1 location(s) · Shandong Provincial Hospital · NCT06829797Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase II
Phase 3 · 1 location(s) · Fujian Cancer Hospital · NCT06793917A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06415669Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07026149Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fet
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07289997Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT06510010First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects Wit
Phase 2 · 1 location(s) · Shanghai Henlius Biotech · NCT07115485Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT06985602Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastr
Phase N/A · 1 location(s) · Xiangdong Cheng · NCT06642857DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 · 11 location(s) · Kyowa Kirin Co., Ltd. · NCT06266299Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastri
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06947291At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT04342910Folfox+Irinotecan+Chemort In Esophageal Cancer
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04656041M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1
Phase 3 · 1 location(s) · FutureGen Biopharmaceutical (Beijing) Co., Ltd · NCT06177041APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced So
Phase 1 · 30 location(s) · Coherus Oncology, Inc. · NCT06657144A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gast
Phase 2 · 70 location(s) · AstraZeneca · NCT07069712A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastr
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06423885Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First
Phase 1/Phase 2 · 51 location(s) · Merck Sharp & Dohme LLC · NCT06469944CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or G
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT04511039BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer
Phase 1 · 1 location(s) · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · NCT06773312
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.